Core View - CoreWeave, Inc. is facing a class action lawsuit for securities fraud due to allegations of misrepresenting customer demand and concealing data center construction delays, which led to a 16% drop in stock price [1] Company Overview - CoreWeave is an AI-focused cloud computing company that operates data centers providing high-performance GPU infrastructure [1] - The company relies on partnerships, including a merger agreement with Core Scientific announced on July 7, 2025 [1] Allegations and Stock Performance - The lawsuit claims CoreWeave overstated its ability to meet customer demand and concealed significant construction delays at its data centers [1] - The stock price dropped significantly after key events: - On October 30, 2025, the stock fell from $139.93 to $131.06, a decrease of over 6%, after Core Scientific failed to secure enough shareholder votes for the merger [1] - On November 10, 2025, the stock dropped from $105.61 to $88.39, a decline of over 16%, following a lowered guidance for revenue and operational metrics due to construction delays [1] - On December 15, 2025, the stock fell from $72.35 to $69.50, a drop of over 3%, after reports of further delays in a major data center project [1] Legal Proceedings - The class action lawsuit is filed in the U.S. District Court for the District of New Jersey, with a lead plaintiff deadline set for March 13, 2026 [1] - The lawsuit asserts claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [1]

Core Viewpoint - Plug Power Inc. is facing a securities fraud class action lawsuit due to alleged misrepresentations regarding a $1.66 billion loan from the U.S. Department of Energy, which contributed to a 17% decline in its stock price [1]. Group 1: Lawsuit Details - A class action lawsuit has been filed against Plug Power and its executives for securities fraud, following significant stock drops attributed to potential violations of federal securities laws [1]. - The lawsuit is pending in the U.S. District Court for the Northern District of New York, under the case caption Ortolani v. Plug Power Inc., et al., No. 1:26-cv-00165 [1]. - Investors have until April 3, 2026, to request to be appointed as lead plaintiffs in the case [1]. Group 2: Allegations and Stock Performance - The lawsuit alleges that Plug Power made misstatements regarding the likelihood of accessing DOE loan funds and constructing hydrogen production facilities [1]. - The stock price of Plug Power dropped significantly following key events: a 6.3% drop after the CEO's departure on October 7, 2025, and a 17.6% drop on November 14, 2025, after news of suspended activities related to the DOE loan program [1]. - The stock fell from a closing price of $2.49 per share on November 13, 2025, to $2.25 per share on November 14, 2025, following reports that the company suspended plans to construct hydrogen facilities [1].

Core Viewpoint - Kaskela Law LLC is investigating Tradeweb Markets Inc. to determine if the company and its officers violated securities laws or breached fiduciary duties related to recent corporate actions [1] Group 1 - The investigation is on behalf of Tradeweb's investors [1] - Kaskela Law LLC specializes in representing investors in securities fraud, corporate governance, and merger & acquisition litigation [2] - Investors seeking more information about their legal rights and options can contact Kaskela Law LLC [2]

Core Viewpoint - An investigation has been announced regarding Soleno Therapeutics, Inc. for potential violations of federal securities laws affecting investors [1] Group 1 - The Law Offices of Howard G. Smith are representing investors who may have suffered losses in Soleno Therapeutics, Inc. (NASDAQ: SLNO) [1] - Investors are encouraged to contact the law firm to discuss potential claims for recovering their losses [1]

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Soleno Therapeutics, Inc. for potential violations of federal securities laws on behalf of investors who may have incurred losses [1] Group 1 - The investigation is prompted by concerns regarding the company's compliance with federal securities regulations [1] - The investigation is specifically aimed at investors who lost money on Soleno Therapeutics, Inc. [1]

Core Viewpoint - A securities class action lawsuit has been filed against Soleno Therapeutics, Inc. for allegedly misleading investors regarding the safety and efficacy of its drug DCCR (VYKAT™ XR) intended for treating hyperphagia associated with Prader-Willi Syndrome [1][4]. Company Overview - Soleno Therapeutics, Inc. is facing legal scrutiny following a significant drop in its stock price after a disappointing report on DCCR, which led to a 26% selloff on November 5, 2025 [2][4]. - The lawsuit claims that Soleno made repeated false statements about the safety and commercial prospects of DCCR, which included assurances of a successful launch that did not align with the actual market performance [4]. Legal Proceedings - The class action lawsuit seeks to represent investors who purchased Soleno common stock between March 26, 2025, and November 4, 2025, with a lead plaintiff deadline set for May 5, 2026 [1][3]. - Hagens Berman, a national shareholders rights firm, is investigating whether Soleno violated federal securities laws and is encouraging affected investors to come forward [3][6]. Market Reaction - The market reacted negatively to the news about DCCR, with Soleno's stock price falling nearly 40% from August 14, 2025, to November 5, 2025, following critical reports from activist short seller Scorpion Capital [5]. - Scorpion Capital raised concerns about the drug's safety, citing reports of children hospitalized for potential heart failure after using VYKAT™ XR, and questioned the integrity of Soleno's clinical trial data [5]. Financial Implications - The lawsuit highlights that DCCR may have lower commercial viability than previously disclosed, with significant undisclosed risks regarding adverse events post-launch [4]. - The investigation by Hagens Berman aims to determine the extent of potential misrepresentation by Soleno regarding the drug's commercial prospects [6].

Core Viewpoint - Nektar Therapeutics is facing a class action lawsuit for securities fraud due to alleged false and misleading statements regarding its clinical trial for the product candidate rezpegaldesleukin [1] Summary by Relevant Sections Class Action Lawsuit - The Schall Law Firm is reminding investors of a class action lawsuit against Nektar Therapeutics for violations of the Securities Exchange Act of 1934 [1] - Investors who purchased Nektar's securities between February 26, 2025, and December 15, 2025, are encouraged to contact the firm before May 5, 2026 [1] Allegations Against Nektar - The complaint alleges that Nektar made false and misleading statements about the integrity of its REZOLVE-AA trial [1] - Issues with patient enrollment for the REZOLVE-AA trial are claimed to have deviated from protocol standards, potentially impacting trial findings negatively [1] - The company's public statements were deemed false and materially misleading throughout the class period, leading to investor damages when the truth was revealed [1]

Core Viewpoint - The Law Offices of Frank R. Cruz is investigating Banco Santander, S.A. for potential violations of federal securities laws on behalf of investors who may have incurred losses [1] Group 1 - The investigation is prompted by a report from the Financial Times dated February 27, 2026, indicating possible legal issues concerning Banco Santander [1]

Core Viewpoint - A class action lawsuit has been announced by Rosen Law Firm on behalf of investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, due to alleged securities fraud [1]. Group 1: Lawsuit Details - The lawsuit claims that defendants made false and misleading statements regarding the REZOLVE-AA trial, including improper enrollment and overstated trial integrity [1]. - Investors who purchased Nektar securities during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A lead plaintiff must be appointed by May 5, 2026, to represent other class members in the litigation [1]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm has a strong track record in securities class actions, having achieved the largest securities class action settlement against a Chinese company and ranking No. 1 for settlements in 2017 [1]. - The firm has recovered hundreds of millions of dollars for investors, including over $438 million in 2019 alone [1]. - Founding partner Laurence Rosen was recognized as a Titan of Plaintiffs' Bar by Law360 in 2020, highlighting the firm's expertise in this area [1].

Core Viewpoint - A class action securities lawsuit has been filed against Kyndryl Holdings, Inc. for alleged securities fraud affecting investors between August 7, 2024, and February 9, 2026 [1][2] Group 1: Allegations - The lawsuit claims that Kyndryl's financial statements during the class period were materially misstated [2] - It is alleged that Kyndryl lacked adequate internal controls and materially understated issues related to these controls [2] - The company was unable to timely file its Quarterly Report on Form 10-Q for the quarter ended December 31, 2025, due to these issues [2] - Defendants' statements regarding Kyndryl's business, operations, and prospects were claimed to be materially false and misleading [2] Group 2: Legal Process - Investors who suffered losses in Kyndryl during the relevant time frame have until April 13, 2026, to request appointment as lead plaintiff [3] - Participation in the lawsuit does not require serving as a lead plaintiff, and there are no out-of-pocket costs for class members [3] Group 3: Law Firm Background - Levi & Korsinsky has a history of securing hundreds of millions of dollars for shareholders and has extensive expertise in complex securities litigation [4] - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the top securities litigation firms in the U.S. [4]